Accepted for Publication: February 7, 2011.
Published Online: April 11, 2011. doi:10.1001/archneurol.2011.69
Author Contributions: Dr Schneider had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Schneider and McShane. Acquisition of data: Schneider, Dagerman, and McShane. Analysis and interpretation of data: Schneider, Dagerman, Higgins, and McShane. Drafting of the manuscript: Schneider, Dagerman, and McShane. Critical revision of the manuscript for important intellectual content: Schneider, Higgins, and McShane. Statistical analysis: Schneider, Higgins, and McShane. Obtained funding: Schneider. Administrative, technical, and material support: Schneider and Dagerman. Study supervision: Schneider.
Financial Disclosure: Dr Schneider reports being an editor on the Cochrane Collaboration Dementia and Cognitive Improvement Group, which oversees systematic reviews of drugs for cognitive impairment and dementia; receiving a grant from the Alzheimer's Association for a registry for dementia and cognitive impairment trials; receiving grant or research support from Baxter, Elan Pharmaceuticals, Johnson & Johnson, Eli Lilly, Myriad, Novartis, and Pfizer; and having served as a consultant for or received consulting fees from Abbott Laboratories, AC Immune, Allergan, Allon, Alzheimer Drug Discovery Foundation, AstraZeneca, Bristol-Myers Squibb, Elan, Eli Lilly, Exonhit, Forest, GlaxoSmithKline, Ipsen Pharma, Johnson & Johnson, Lundbeck, Myriad, Medavante, Medivation, Merck, Merz, Novartis, Pfizer, Roche, sanofi-aventis, Schering-Plough, Toyama, and Transition Therapeutics. Dr McShane reports being coordinating editor on the Cochrane Collaboration Dementia and Cognitive Improvement Group, which oversees systematic reviews of drugs for cognitive impairment and dementia; receiving a grant from the Alzheimer's Association for a registry for dementia and cognitive impairment trials; and receiving grant or research support from Abbott Laboratories, Lundbeck, Novartis, and Medivation.
Funding/Support: Dr Higgins is supported by Medical Research Council grant U.1052.00.011. This research was supported in part by the California Alzheimer Disease Center program and the University of Southern California Alzheimer Disease Research Center (National Institutes of Health grant P50 AG05142).
Additional Contributions: We thank H. Lundbeck A/S for providing additional data and Zakaria Shaikh, MPH, MBA, for assistance with data extraction and review.